お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
964902

緑内障治療市場-成長、動向、および予測(2020年~2025年)

Glaucoma Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
緑内障治療市場-成長、動向、および予測(2020年~2025年)
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

緑内障治療市場の成長の主な要因には、緑内障の有病率の増加、緑内障についての意識を高めるためのイニシアチブの高まり、および眼科分野における技術の進歩が含まれます。

緑内障は、世界で2番目に多い失明の原因です。これは通常、眼圧の上昇が原因で発生します。主な治療目標は、眼圧を下げることです。これは、房水の分泌を減らすか、その排液を増やすことによって行われます。緑内障はまた、開放隅角(広角)、慢性緑内障および閉塞隅角(狭角)、および急性うっ血性緑内障に分類されています。緑内障の薬は症状を軽減しますが、この状態の完全な治療法はありません。

WHOによると、2019年に世界中で6000万人以上の患者が緑内障に苦しんでいます。緑内障調査財団によると、米国では、12万人以上の患者が緑内障で失明しています。したがって、緑内障の症例の増加により、市場は予測期間にわたって高い成長をすると予想されます。

当レポートでは、緑内障治療市場を調査し、市場概要、市場の成長要因および阻害要因の分析、タイプ別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 緑内障の有病率の増加
    • 緑内障についての意識を高めるためのイニシアチブの高まり
    • 眼科の分野における技術の進歩
  • 市場の抑制要因
    • 製品に関連する副作用
    • 厳格な承認プロセス
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 適応症別
    • 開放隅角緑内障
    • 閉鎖隅角緑内障
    • 続発性緑内障
    • 先天性緑内障
    • その他
  • 医薬品クラス別
    • プロスタグランジン類似体
    • ベータ遮断薬
    • アルファアゴニスト
    • 炭酸脱水酵素阻害剤
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Aerie Pharmaceuticals Inc.
    • Akorn, Incorporated
    • Abbvie Inc. (Allergan Plc)
    • Bausch Health (Bausch & Lomb Incorporated)
    • Inotek Pharmaceuticals
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc
    • Santen Pharmaceutical Co., Ltd.

第7章 市場機会と動向

目次
Product Code: 66854

The major factors for the growth of the glaucoma treatment market include the increasing prevalence of glaucoma, rising initiatives to increase awareness about glaucoma, and technological advancements in the field of ophthalmology.

Glaucoma is the second leading cause of blindness, globally. This generally happens due to raised intraocular tension. The main therapeutic goal is to lower the intraocular tension. This is done either by reducing the secretion of aqueous humor or increasing its drainage. Glaucoma has also been divided into an open angle (wide angle), chronic glaucoma and angle-closure (narrow-angle), and acute congestive glaucoma. Although the drugs of glaucoma reduce the symptoms, there is no complete cure for this condition. The drugs used for the treatment of glaucoma are segmented into beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, prostaglandin analogs, and combination medications.

According to WHO estimates, more than 60 million patients are suffering from glaucoma worldwide, as per 2019 statistics. According to the Glaucoma Research Foundation, in the United States, more than 120,000 patients are blind from glaucoma. Thus, owing to the rising cases of glaucoma the market is expected to witness high growth over the forecast period.

Key Market Trends

Prostaglandin Analogs is the Segment by Drug Class that is Expected to Witness Fastest Growth Over the Forecast Period

Prostaglandin analogs work by increasing the outflow of intraocular fluid from the eye. They have few systemic side effects but are associated with changes to the eye itself, including change in iris color and growth of eyelashes. Depending on the individual, one brand of this type of medication may be more effective and produce fewer side effects.

Prostaglandin analogs are taken as eye drops. They are effective at reducing intraocular pressure in people who have open-angle glaucoma. Latanoprost and some formulations of bimatoprost and travoprost are now available in generic form. Tafluprost is a preservative-free prostaglandin analog.

The demand for these drugs is expected to rise as the incidence of glaucoma has increased over the past few years due to the aging population. Moreover, the incidence of the disease is expected to increase in the future as the population aged 60 years and over are expected to increase from 12.7% in 2017 to 21.3% by 2050, as per a 2017 report by the United Nations. Increasing geriatric population is expected to increase the prevalence of glaucoma, as the disaese is more prevalent in the elderly. Hence the demand for Prostaglandin Analogs is also expected to increase, which will boost the market growth.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest glaucoma treatment market owing to the rising cases of glaucoma and the presence of better healthcare infrastructure. As per the data published by the BrightFocus Foundation more than 3 million Americans are living with glaucoma and open-angle glaucoma is the most common form of glaucoma.

Furthermore, glaucoma costs to the United States economy around USD 2.86 billion every year in direct costs and productivity losses. Also, there are various organizations in the United States creating awareness regarding glaucoma which is expected to propel the overall growth of the market.

Competitive Landscape

The market studied is a consolidated market owing to the presence of few major market players. Some of the market players are AERIE PHARMACEUTICALS, INC., Akorn, Incorporated, Allergan Plc, Bausch & Lomb Incorporated, Inotek Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc, and Santen Pharmaceutical Co., Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Glaucoma
    • 4.2.2 Rising Initiatives to Increase Awareness about the Glaucoma
    • 4.2.3 Technological Advancements in the Field of Ophthalmology
  • 4.3 Market Restraints
    • 4.3.1 Side Effects associated with the Products
    • 4.3.2 Stringent Approval Process
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Indication
    • 5.1.1 Open Angle Glaucoma
    • 5.1.2 Closed Angle Glaucoma
    • 5.1.3 Secondary Glaucoma
    • 5.1.4 Congenital Glaucoma
    • 5.1.5 Others
  • 5.2 By Drug Class
    • 5.2.1 Prostaglandin Analogs
    • 5.2.2 Beta Blockers
    • 5.2.3 Alpha Agonist
    • 5.2.4 Carbonic Anhydrase Inhibitors
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aerie Pharmaceuticals Inc.
    • 6.1.2 Akorn, Incorporated
    • 6.1.3 Abbvie Inc. (Allergan Plc)
    • 6.1.4 Bausch Health (Bausch & Lomb Incorporated)
    • 6.1.5 Inotek Pharmaceuticals
    • 6.1.6 Merck & Co., Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer Inc
    • 6.1.9 Santen Pharmaceutical Co., Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.